Latest Administration News

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Altamin Limited has launched a $6.46 million accelerated entitlement offer to fund exploration at its Lazio and Gorno projects, while excluding shareholders in certain jurisdictions due to regulatory constraints.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Gold Mountain Limited has announced a fully underwritten $1.5 million entitlement offer alongside a $2 million placement to accelerate exploration activities in Brazil and Papua New Guinea. The capital raising, discounted by 40% to recent share prices, is underwritten by major shareholder José Luis Manzano, who may increase his stake to nearly 20%.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

Bravura Solutions has appointed Colin Greenhill as its new Group CEO, effective 1 January 2026, following a comprehensive global search. Greenhill brings over 15 years of leadership experience in financial services software, signaling a strategic step forward for the company.

Super Retail Group Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 0.34 per share and a special dividend of AUD 0.30 per share, alongside an updated dividend reinvestment plan price of AUD 16.90.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

XRF Scientific Limited has confirmed its fully franked ordinary dividend for the 2025 financial year and updated details of its Dividend Reinvestment Plan price, offering shareholders a clear view on income and reinvestment options.

Manuka Resources has received a binding debt offer to refinance existing obligations and support the restart of its Wonawinta silver and gold processing plant in early 2026, leveraging current high metal prices.